OS1.1 Plasma PD-L1 levels over time differ between glioblastoma and lower-grade glioma patients

BACKGROUND: Immune modulating therapies are a promising treatment approach in patients with primary brain tumors, however their clinical efficacy is still under investigation as the systemic inflammatory responses are potentially challenged by the brain’s tight immune regulatory mechanisms. Here, we...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Mair, M, Ilhan-Mutlu, A, Pajenda, S, Widhalm, G, Dieckmann, K, Hainfellner, J A, Marosi, C, Wagner, L, Preusser, M, Berghoff, A S
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Oral Presentations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795000/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.014
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados